Android operating systems only,
with the iOS version expected in the
coming months.
Abbott's FreeStyle Libre and
FreeStyle Libre 2 systems remain
listed on the NHS Drug Tariff and
available on prescription for people
with diabetes eligible for Flash
Glucose Monitoring.
Abbott's FreeStyle Libre system is
designed to change the way glucose
is monitored in people with diabetes
and ultimately help them improve
their diabetes managementii. The
system measures glucose levels using
a sensor worn on the back of the
upper arm, eliminating the need for
routine finger-prickingiii.
Libre 1, 2 and 3
Three FreeStyle Libre systems;
FreeStyle Libre, FreeStyle Libre 2 and
FreeStyle Libre 3 are now available in
the UK, offering a range of glucose
monitoring solutions depending on
individual need.
Numerous clinical studies have
shown that people who use the
FreeStyle Libre systems experienced
improved glucose controliv, increased
time in target rangev, reduced
hyperglycaemia (high blood glucose)
and hypoglycaemia (low blood
i Data on file, Abbott Diabetes
Care, Inc.
ii Bolinder, Jan, et al. Novel
glucose-sensing technology
and hypoglycaemia in Type 1
diabetes: a multi-center, nonmasked,
randomized, controlled
trial. The Lancet 388.10057
(2016): 2254-2263.
iii Additional testing of glucose
levels using a blood glucose
meter is required if symptoms
are not consistent with system
readings or alarms.
iv Eeg-Olofsson et al. Sustainable
HbA1c decrease at 12 months for
adults with Type 1 and Type 2
Diabetes using the FreeStyle
Libre System: a study within the
National Diabetes Register in
Sweden.
v Lang J, Jangam SR, Dunn TC,
Hayter G. Expanded real-world
use confirms strong association
between frequency of flash
glucose monitoring and glucose
control.
vi Dunn TC, Xu Y, Hayter G, Ajjan
RA. Real-world flash glucose
monitoring patterns and
associations between selfmonitoring
frequency and
glycaemic measures: a European
analysis of over 60 million
glucose tests. Diabetes Res Clin
Pract. 2018;137:37-46.
vii Fokkert M, van Dijk P, Edens
M, et al. Improved well-being
and decreased disease burden
after 1-year use of flash glucose
monitoring (FLARE-NL4). BMJ
Open Diab Res Care. 2019;7(1):
e000809. doi:10.1136/
bmjdrc-2019-000809.
viii Data based on the number
of users worldwide for the
FreeStyle Libre system
compared to the number of
users for other leading personal
use, sensor-based glucose
monitoring systems. Data on file,
Abbott Diabetes Care, Inc.
DEXCOM
In our news pages in this issue we
reported that Dexcom's G7 has
gained a CE Mark, meaning it will
soon be marketed across Europe,
including in the UK. The new version
of the highly accurate sensor is
significantly smaller.
So, how Accurate is Dexcom G7
Continuous Glucose Monitoring?
In March 2022, a clinical trial of
Dexcom G7 Continuous Glucose
Monitoring (CGM) showed it to be
safe and accurate. The seventhgeneration
device (Dexcom G7) was
tested during 10.5 days in adults
with diabetes, as reported in the
peer-reviewed journal Diabetes
Technology & Therapeutics (DTT).
Adults with either type 1 or
type 2 diabetes participated at 12
investigational sites across the
U.S. Measurements from the G7
CGM were compared with those
of a conventional YSI glucose
analyzer. Participants wore sensors
concurrently on the upper arm and
abdomen. The performance of the
sensors was assessed across the 10.5-
day study period, different glucose
concentration ranges, and various
rates of glucose changes.
glucose)vi, and lower HbA1c (average
glucose concentration over 3
months)11 - all of which contribute to
improving the health of people with
diabetes. Data also show that use of
the FreeStyle Libre system reduces
diabetes-related hospitalisations
and workplace absenteeism11. These
aspects also promote an increase in
quality of life.vii
As the most widely used sensorbased
glucose monitoring system in
the world , Abbott's FreeStyle Libre
product portfolio has changed the
lives of nearly 4 million people in over
50 countries around the world.viii
www.freestylelibre.co.uk
Abbott's FreeStyle Libre 3